Diabetes drug may double as bone booster for fracture-prone patients
NCT ID NCT06050577
First seen Feb 20, 2026 · Last updated May 20, 2026 · Updated 10 times
Summary
This study looks at whether oral semaglutide, a daily pill for type 2 diabetes, can improve bone health in people aged 50-85 who also have weak bones (osteopenia). Over 52 weeks, researchers will measure bone turnover markers, bone density, and strength. The goal is to see if this drug can help prevent fractures in this high-risk group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Odense University Hospital
Odense, 5000, Denmark
Conditions
Explore the condition pages connected to this study.